

NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL (NAFDAC)



STRATEGIC PLAN

(2024 – 2027)




Table of Contents

LIST OF ABBREVIATIONS 3

FOREWORD 4

CHAPTER ONE 5

INSTITUTIONAL ANALYSIS 5

CHAPTER TWO 6

VISION, MISSION, AND CORE VALUES 6

CHAPTER THREE 7

STRATEGIC FOCUS, GOALS AND OBJECTIVES 7

CHAPTER FOUR 9

STRATEGIC FRAMEWORK 9

CHAPTER FIVE 10

RESULT FRAMEWORK & ACTIVITY TIMELINE 10

LIST OF ABBREVIATIONS

ADR: Adverse Drug Reaction	GAAP: Generally Accepted Accounting Principles	NEIPS -
AEFI: Adverse Events Following Immunization	GDP: Good Distribution Practices	NICIS - Nigerian Integrated Customs Information System
APIs - Active Pharmaceutical Ingredients	cGMP - Current Good Manufacturing Practices	NGO - Non-Governmental Organizations
ATM: HIV/AIDs, Tuberculosis and Malaria	GS1: Global Standard	NHREC - Nigerian Health Research Ethics Committee
AMR: Anti-Microbial Resistance	GMP: Good Manufacturing Practices	PA - Public Affairs
AMU: Anti-Microbial Usage	GHP: Good Hygienic Practices	PPEs: Personal Protective Equipment
BCMS: Business Continuity Management System	HRM - Human Resource Management	PO: Purchase Orders
CBN - Central Bank of Nigeria	KPIs: Key Performance Indicators	PID - Port Inspection Directorate
CEO - Chief Executive Officer	HRMIS - Human Resources Management Integrated System	PIDCARMS:
CER - Chemical Evaluation & Research	IA - Institutional Assessment/Analysis	PRASCOR - Pharmacovigilance Rapid Alert System for
CRIA - Clean Report of Inspection Analysis	ICT - Information Communication Technology	Consumer Reporting
CTD - Common Technical Documents	IEC: Information and Education Communication Materials	PRS - Planning Research & Statistics
CTAC: Community Treatment and Care	ICSRs: Individual Case Safety Reports	PV - Pharmacovigilance
DER - Drug Evaluation and Research	I&E - Investigation and Enforcement	PMS - Post Market Surveillance
DG - Director General	ICH - International Conference on Harmonization	PQM - Product Quality Management
D, LS (F&C): Director Laboratory Services (Food and Chemicals)	INGO - International Non-Governmental Organization	RMP: Remote Patient Monitoring
D, LS (Drug): Director Laboratory Services, Drug	IPSAS: International Public Sector Accounting System	Q1: Quarter one
D, ALS: Director, Agulu Laboratory Services	ISO - International Organization for Standardization	Q2: Quarter two
D, KLS: Director Kaduna Laboratory Services	ISMS: Information Security Management System	Q3: Quarter three
D, VBM-LS: Director Vaccines, Biologics and Medical Devices	INCB - International Narcotics Control Board	Q4: Quarter four
Laboratory Services	LIMS - Laboratory Information Management System	QA - Quality Assurance
D, DER: Director, Drug Evaluation and Research Directorate	LS - Laboratory Services	QC - Quality Control
D, DR&R: Director, Drug Registration and Regulatory Affairs	NHREC: National Health Research Ethics Committee	QMS - Quality Management System
D, FR&R: Director, Food Registration and Regulatory Affairs	NICIS: Nigeria Integrated Customs Information System	R&R - Registration and Regulatory Affairs
D, PRS: Director Planning Research and Statistics Directorate	NDEPS: National Economy Policy and Strategy	REMITA: Payment gateway for Federal Government Funds generated
D, VMAP: Director Veterinary Medicines & Allied Products	NDPR: Nigeria Data Protection Regulation	from levies, taxes and tariffs
D, HRM: Director, Human Resource Management Directorate	NGEA: Nigeria Government Enterprise Architecture	SF - Strategic Focus
D, PID: Director, Ports Inspection Directorate	MAHs: Marketing Authorization Holders	SFs - Substandard and Falsified Medicines
D, PA: Director, Public Affairs Unit	MAS - Mobile Authentication Service	SO - Strategic Objective
D, NCS: Director, Narcotics and Control Substances Directorate	MDGs - Millennium Development Goals	SOP - Standard Operating Procedure
D, LSO: Director, Lagos State Office	MDAs - Ministries, Departments and Agencies	SWOT - Strengths, Weaknesses, Opportunities and Threats
D, FCT: Director, Federal Capital Territory	M&E - Monitoring and Evaluation	TMC - Top Management Committee
D, I&E: Director, Investigation and Enforcement Directorate	MRA - Medicines Regulatory Agencies	UNICEF - United Nations Children's Fund
D, LeSD: Director, Legal Services Directorate	MoU - Memorandum of Understanding	UNIDO - United Nations Industrial Development Organization
D, CER: Director Chemical Evaluation and Research Directorate	MSMEs - Micro, Small & Medium Enterprises	USAID - United States Agency for International Development
DHIS - District Health Information System	NAFDAC - National Agency for Food and Drug Administration	USAT: User Satisfaction survey
EPMS: Employee Performance Management System	and Control	VAT: Value Added Tax
F&A - Finance and Accounts	NAPAMS - NAFDAC Automated Product Administration &	VMAP - Veterinary Medicines & Allied Products
FDA - Food and Drug Administration (United States)	Monitoring System	WHO - World Health Organization
FMoH - Federal Ministry of Health	NCS - Nigerian Customs Service/Narcotics and Controlled	WHO-GTB - World Health Organization-Global Benchmarking
FSAN - Food Safety and Applied Nutrition	Substances	Tool
FPPs - Finished Pharmaceutical Products		

FOREWORD

I am delighted to present to you the NAFDAC Strategic Plan 2023–2027, which outlines the strategic visions and goals we have identified to help the Agency realize its full potential and better fulfil its mission to promote the quality and safety of food, drugs, chemicals, cosmetics, detergents, medical devices, and bottled water by ensuring adherence to global best practices to protect public health.

The process of formulating this current Strategic Plan has given us the opportunities to take stock of past successes and failures, to determine our goals and objectives in the light of current challenges and to put forward strategies to address the challenges and also respond to changes in the regulatory milieu. The strategies are also aligned with the renewed Hope Agenda of the Federal Government of Nigeria.

The strategic themes attest to our commitment to safeguard public health through our core values of professionalism, resilience, integrity, dedication as well as exhibiting excellence in our daily efforts to remain customer-focused, Agency-minded.

Our strategies for safeguarding public health are aimed at instituting an effective and efficient regulatory system that ensures only the right quality Food, Drugs and other regulated products are manufactured, exported, imported, advertised, distributed, sold, and used.

To implement our strategic objectives, we need to develop an enabling environment in which our human, financial and physical resources are appropriately allocated and deployed to help us attain sustainable excellence in our regulatory processes. Accordingly, the Agency aims to remain a world-class regulator that ensures the availability of quality and safe food, drugs, and other NAFDAC-regulated products to the consuming public.

The Strategic Plan represents the concerted efforts of our staff and stakeholders, whose valuable feedback and inputs have been incorporated in this document. I would like to acknowledge the work of the Strategic Plan development committee coordinated by the PRS Directorate who led the process of preparing this Strategic Plan.

I am sure that, with the collaboration of our hardworking staff and external stakeholders the goals we aspire to accomplish will in time translate into milestones of which we can be proud of. I invite you to read the Plan and collaborate with the Agency to effectively safeguard the health of our people.



Prof. Christianah Mojisola Adeyeye, FAS

DIRECTOR-GENERAL (NAFDAC)

CHAPTER ONE

INSTITUTIONAL ANALYSIS

The Agency's 2018-2023 Strategic Plan expired by the end of December 2023. In line with the global best practices, the plan was evaluated after its expiration on 1st of January 2024. It is pertinent to mention that there was a mid-term review aimed at ensuring that the Agency remained aligned with its goals, adapted to changing environments, and optimally utilized resources. The post-plan evaluation was to assess the level of implementation of the Plan, assess the factors that may have facilitated or hindered the achievement of set goals, and compile lessons learned that would serve as inputs into the next Strategic Plan. The evaluation further ensured that all staff members have a clear understanding of the Agency's direction, which promotes unity and fosters collective efforts towards common goals.

It is therefore worthy of note that a rich harvest of information was gathered from the post-plan evaluation as the data collected and analyzed provided background material for discussing and identifying priority areas for action in this current Strategic Plan. The 2018-2023 Strategic Plan had 84% level of achievement, thus showing that the Agency is on the right track in safeguarding public health.

The challenges confronting the Agency however include inadequate funding, inadequate staff strength, weak legislation etc.

Nevertheless, the evaluation of the last Strategic Plan revealed the existence of the following opportunities in the system that can benefit the Agency; WHO Pre-Qualification status of our Central Drug Laboratory in Yaba, Lagos which has increased the capacity of the laboratory to serve as the Regional Centre for Regulatory Excellence in Drug Analysis and as a reference laboratory for testing of program medicines for Global Fund and other International Agencies and organizations. This has a huge capacity to increase revenue generation. The attainment of WHO ML3 places the Agency on a pedestal towards achieving ML4 and WHO Listed Authority (WLA) Status. The status affords Nigeria the opportunity for global trade of Nigeria-made pharmaceuticals in addition to making local pharmaceutical manufacturers more competitive in AfCFTA. Other identified opportunities are well-equipped and certified laboratories; the availability of NAFDAC Offices in 36 states and FCT as well as highly trained and resourceful workforce.

Aware of the above opportunities and taking note of the lessons learned from the implementation of the last Strategic Plan (2018-2023) the Agency's management has therefore identified strategic areas to better position the Agency to safeguard public health. These strategic foci include **Strong Leadership and Governance, Institutionalization of Best Practices, Safety and Quality of Regulated Products, Continuous Monitoring along the Supply Chain, and Efficient Financial and Performance Management.**

CHAPTER TWO

VISION, MISSION, AND CORE VALUES

VISION

To be a world-class regulator that ensures the availability of quality and safe food, drugs, and other NAFDAC-regulated products.

MISSION

To protect and promote the public health by instituting an effective and efficient regulatory system that ensures only the right quality Food, Drugs and other regulated products are manufactured, exported, imported, advertised, distributed, sold, and used.

CORE VALUES

NAFDAC staff members are Customer-focused, Agency-minded, and are guided by the following core values **‘PRIDE’**:

1. Professionalism
2. Resilience
3. Integrity (Transparency & Good Governance)
4. Dedication & Commitment
5. Excellence

CHAPTER THREE

STRATEGIC FOCUS, GOALS AND OBJECTIVES

NAFDAC in pursuance of its mandate has the underlisted five (5) Strategic Pillars to achieve its goals and objectives in the years 2024 to 2027.

Strategic Pillars

1. Strong Leadership and Governance
2. Institutionalization of Best Practices
3. Safety and Quality of Regulated Products
4. Continuous Monitoring along the Supply Chain
5. Efficient Financial and Performance Management

1. Strong Leadership and Governance

Goal: To sustain a Transparent Quality-Driven Management Structure for a Strong Regulatory Framework

Strategic Objectives and Interventions

1.1 Ensure Disciplined and Motivated Management and Workforce

- Provision of additional human resources
- Provision of additional operational vehicles, Property, Plant and Equipment, including Personal Protective Equipment.
- Improvement of Staff emoluments.
- Provision of a safe and work-friendly environment.

1.2 Strengthen Regulatory Framework

- Amendment of NAFDAC Laws
- Develop/ Review regulations and guidelines for regulatory processes.
- Diligent prosecution/defense of civil and criminal cases.

1.3 Strengthen Quality Management System and WHO Global Benchmarking Tool principles

- Sustain QMS Certification.
- Attain WHO GBT ML 4 Vaccine Lot Release.
- Attain WHO Listed Authority (WLA).

1.4 Strengthen Overarching Information and Communication Technology

- Expansion of Digital transformation of Agency's Processes for Efficiency and Effectiveness.
- Implement relevant ISO certifications and comply with ICT Policy and regulations.
- Increase Internet bandwidth provisioning and Cloud hosting services.
- Increase IT working tools – PCs, Laptops, tablets, Servers, Printers.

2 Institutionalization of Best Practices

Goal: To improve the Corporate Image of the Agency and the Country.

Strategic Objectives and Interventions

2.1 Improve efficiency in all NAFDAC Processes

- Continued monitoring and improvement of Cycle time of key processes.
- Development of electronic processing for Listing certificate and Permit to Clear.
- Sustenance of the issuance of Permit to Import controlled drugs and other classes of chemicals.
- Deployment of process improvement modules on electronic platforms (PIDCARMS, LIMS, NAPAMS, AHRMS etc.)

2.2 Build Capacity of Staff and Stakeholders through targeted training and development programmes.

- Implementation of training and staff development programmes to improve staff performance.
- Increase collaborations with stakeholders through sensitization workshops.
- Participation at Statutory meetings both local and international.

2.3 Improve Customer Satisfaction through Effective Communication and Complaint Resolution.

- Establish an efficient communication system for increased stakeholders' participation
- Improve on the effective customer complaint resolution system.

2.4 Strengthen Laboratory System for effective service delivery

- Maintain compliance with requisite standards and achieve accreditation from recognized bodies to demonstrate excellence
- Timely procurement of consumables and laboratory equipment with cutting-edge technology to support testing.

3 Safety and Quality of Regulated Products

Goal: To ensure the quality and safety of regulated products that are fit for both local and/or foreign markets

Strategic Objectives and Interventions

3.1 Reduce Significantly Substandard and Falsified/Counterfeit Medical Products, Unwholesome Foods, and other NAFDAC-regulated products.

- Strengthen GMP inspections for Foreign and Local Facilities.
- Strengthen Intelligence and Enforcement activities.
- Enforce ban on sale of pharmaceutical products in open drug markets.
- Strengthen the capacity of local pharmaceutical and other regulated product manufacturers.
- Sustain routine surveys on the level of substandard and falsified medicines.

3.2 Strengthen Clinical Trials

- Optimize Clinical Trials.
- Conduct periodic review meetings with CTAC, NHREC etc

3.3 Strengthen the Regulatory Environment for the Safety of food, feeds, medical products and agro-chemicals and other NAFDAC-regulated products.

- Improve routine inspection and monitoring of Drugs, cosmetics, food/feeds production facilities across the 36 states including FCT.
- Strengthen Field Trial Evaluation/ Bio-efficacy Trial of Pesticides and Agrochemicals
- Institute surveillance system for Anti-microbial agent and Agrochemical in Nigeria

3.4 Ensure Strict Utilization of Narcotics Drugs and Controlled Substances for Medical and Scientific Purposes

- Improve warehouse inspection and sales verification of outlets for narcotic drugs as well as controlled substances to prevent diversion and abuse.
- Risk categorization of importers and manufacturers of narcotic medicines
- Assessment of finished Narcotics utilized by health facilities.

3.5 To strengthen the regulatory framework for the sound management of chemicals

- Improve warehouse inspection and sales verification of outlets for chemicals.
- Improve inspection and monitoring of chemical production and storage facilities.
- Full digitization of all CER operations including digital listing certificate and permit to clear restricted chemicals.

4 Continuous Monitoring along the Supply Chain

Goal: To Safeguard Public Health

Strategic Objectives and Interventions

4.1 Strengthen Post-marketing Surveillance (PMS) of Food and Medical Products

- Improve PMS inspections at wholesale, distributors, and retail facilities across the 36 states including FCT.
- Effective recall of violating products from the supply chain to protect the public.
- Risk-based categorization of food and medical products into high, medium, and low categories.
- Increase the scope of GDP Inspections
- Implementation of Traceability Systems for all pharmaceutical products (using HIV/AIDS, Tuberculosis, Malaria (ATM) commodities and Narcotic drugs as a pilot).

4.2 Strengthen the Pharmacovigilance System for effective Adverse Event reporting and assessment

- Sustain Adverse Event Reporting drive.
- Improve PV inspections of Pharmaceutical Manufacturers and Marketing Authorization Holders across the 36 states including FCT

5 Efficient Financial and Performance Management

Goal: To Promote, Sustain, and reinforce transparency and accountability in the management of the financial resources of the Agency.

Strategic Objectives and Interventions

5.1 Sustain a Responsible and Balanced Budgeting System.

- Enhance processes for tracking Resource Utilization
- Sustain the Standardized Financial Reporting Format
- Sustain existing Internal Control Systems.

5.2 Strengthen the Performance Management System of the Agency

- Strengthen the survey system for Data Integrity and evidence-based decision.
- Strengthen the Monitoring and Evaluation System.


5.3 Effective Revenue Management and Sustainability of Financial Best Practices

- Quarterly Revenue Monitoring to ensure strict adherence to tariff.
- Utilization of user fees for intended purposes
- Development of annual work plans to set goals, track progress, and ensure effective allocation of resources.

5.4 Strengthen Procurement Process

- Institutionalize a Transparent Procurement and Tendering process.
- Reduce Procurement Cycle.

**CHAPTER FOUR
STRATEGIC FRAMEWORK**



S/N	OBJECTIVES	INITIATIVE	KPIs	PERFORMANCE TARGET	JOURNEY TRACKER	RESPONSIBLE	TIMELINE		2024				2025				2026				2027							
							OUTPUT	ACTIVITY	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4	Q 1	Q 2	Q 3	Q 4				
			product type)			D Zones																						
			Percentage of Product Samples Analysis requests carried out within timeline (Disaggregate by product type)	90% of product samples analysed within timeline	Achieve 90% by 2024 and sustain till 2027	D LS	Received product samples processed timely	Receive and process samples through LIMS platforms	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
			Percentage of Imported Clearance approved within timeline (Disaggregate by product type)	90% of import clearance issued within timeline	Achieve 90% by 2024 and sustain till 2027	D PID	Received import clearance processed timely	Receive and process import clearance applications through PIDCARMS platforms	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
			Percentage of Exports Certificates issued within timeline (Disaggregate by product type)	90% of Exports Certificates issued within timeline	Achieve 90% by 2024 and sustain till 2027	D PID	Received Exports Certificates applications processed timely	Receive and process Exports Certificates applications through PIDCARMS platforms	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
			Percentage Import Permit requests Issued within timeline (Disaggregate by product type)	90% of import permit issued within timeline	Achieve 90% by 2024 and sustain till 2027	D CER D NCS D VMAP	Received import permit request processed timely	Receive and process import permit applications through Single Window Trade Portal	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
		Deployment of process improvement modules on electronic platforms	Fully functional and integrated electronic platforms with external and Internal systems	90% of NAFDAC electronic platforms Integrated	60% by 2024, 70% by 2025, 80% by 2026, 90% by 2027	Head ICT	NAFDAC electronic platforms Integrated	1. Integrate NAFDAC electronic platforms such as NAPAMS, LIMS, PIDCARMS etc. 2. Integrate NAFDAC electronic platforms with external systems such as NICIS, SWT, REMITA etc.																				
2.2	Build the Capacity of Staff and Stakeholders through targeted training and	Implementation of training and staff development programs to improve staff	Percentage of approved training plan implemented	To coordinate 70% implementation of yearly approved training plans	Achieve 70% implementation of approved plans yearly	D, PRS	1. Approved training plans implemented. 2. Staff trained	Coordinate trainings and awareness programmes for staff and stakeholders. Collate Assessment of Staff Training Needs	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x

S/N	OBJECTIVES	INITIATIVE	KPIs	PERFORMANCE TARGET	JOURNEY TRACKER	RESPONSIBLE	TIMELINE		2024				2025				2026				2027					
							OUTPUT	ACTIVITY	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4		
	development programmes	performance	Training and development hours per employee	20 hours training and development per employee achieved yearly	Achieve 20 hours training and development per employee yearly	D, PRS	1. Approved training plans implemented. 2. Staff trained	Monitor and document implementation of staff training	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x		
			Employee Skill Gap Assessment Rate	Employee skill Gap reduced to 10% by 2027	30% by 2024, 20% by 2025, 15% by 2026, 10% by 2027	D, PRS	Skill Gap survey conducted	Conduct survey to assess skill gap of staff				x				x				x				x		
			Proportion of implemented training stepped down	100% of trainings stepped down	80% by 2024, 95% by 2025, 100% by 2026, sustain to 2027	D, PRS	Step down trainings conducted	Conduct step down training for all external trainings attended	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x		
			Stakeholder Engagement Rate	To conduct 90% of planned sensitization workshops yearly	Achieve 90% implementation of planned sensitization workshops yearly	D,PA D, PRS D (Zones) All relevant Directors	Planned sensitization workshops conducted	Conduct sensitization workshops				x				x				x				x		
		Increase collaborations with stakeholders and Partners	Partnership growth rate	10% growth in number of Partners achieved yearly	10% partnership growth yearly	OTIR All relevant Directors	Partnership growth achieved	1. Carry out advocacy visit to partners 2. Sign MoUs with partners				x				x				x				x		
			Partnership Fund expansion rate	10% growth in Partners funding achieved yearly	10% partnership fund expansion yearly	D F&A	Partnership fund expansion achieved	1. Carry out advocacy visit to partners 2. Sign MoUs with partners				x				x				x				x		
			Percentage of statutory meetings attended	Attend 80% of statutory meetings	Attend 80% statutory meetings yearly	DGO All relevant Directors	Statutory local and international meetings attended	Attend approved statutory meetings as scheduled				x				x				x				x		
		2.3	Improve Customer Satisfaction through Effective Communication and Complaint Resolution	Establish an efficient communication system for increased stakeholders participation	Proportion of approved information disseminated through print, electronic and social media	Disseminate 85% of approved information on NAFDAC activities disseminated through print, electronic and social media yearly	Achieve 85%, disseminated yearly through print, electronic, and social media	D, PA Head, ICT	Approved information on NAFDAC activities disseminated through print, electronic and social media	Continuously convey the Agency's programmes (sensitization, workshops, and events, Press Releases, DGs keynotes/speeches/addresses) on our Digital platforms Quarterly press releases and Weekly NAFDAC and your Health Television programme	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x

S/N	OBJECTIVES	INITIATIVE	KPIs	PERFORMANCE TARGET	JOURNEY TRACKER	RESPONSIBLE	TIMELINE		2024				2025				2026				2027			
							OUTPUT	ACTIVITY	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
			Social Media followers growth rate	100% growth achieved yearly	Achieve 100% yearly	DGO D PA	Social media platforms verified	1. Verify all NAFDAC social media platforms																
			Percentage of approved content published on website within the timeline	To host 90% of approved information on NAFDAC website within the timeline	Achieve 90% yearly	Head, ICT All relevant Directorates	Approved information on NAFDAC hosted on the website	Hosting of approved information on NAFDAC website	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
			IEC Materials dissemination rate (Dissagregate by location)	To print 100% of approved IEC material and disseminate every year	Achieve 100% yearly	DGN D, PA	Approved Information and Education Communication (IEC) materials printed and disseminated	Printing and dissemination of Information and Education Communication (IEC) materials	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
		Improve on the effective customer complaint resolution system	Proportion of customers' complaints resolved within stipulated timelines	90% of complaints resolved within timelines by 2027	Achieve 75%-2024 80%-2025 85% -2026 90% -2027	Head, Reforms All Directorates Zones/States	Customers' Complaints resolved within stipulated timelines.	Receiving and escalate complaints to relevant Directorates within 24 hours. Directorates resolve issues within stipulated timelines		x				x				x				x		
			Complaint resolution ratio	90% of received complaints resolved	Achieve 75%-2024 80%-2025 85% -2026 90% -2027	Head, Reforms All Directorates Zones/States	Customers' Complaints resolved within stipulated timelines.	Receiving and escalate complaints to relevant Directorates within 24 hours. Directorates resolve issues within stipulated timelines		x				x				x				x		
2.4	Strengthen Laboratory System for effective service delivery	Maintain compliance with requisite standards and achieve accreditation from recognized bodies to demonstrate excellence	Proportion of NAFDAC laboratories with WHO Pte-Qualification status	Sustain WHO Pre-Qualification for CDCL Yaba and Achieve WHO Pre-Qualification for 2 Laboratories (KLS, ALS) by 2027	Achieve 100% by 2027	DGN D, LS(D) D KLS D ALS	WHO Pre-qualification status achieved for 3 Laboratories	1.Regular training of laboratory staff 2. Pre-Qualification of all laboratories 3. Internal Audits 4. A Scope extension to cover other testing e.g. AAS for herbal samples. 5. Annual calibration of equipment and other measuring devices. 6. Preventive maintenance agreement with the equipment suppliers to ensure equipment are functioning optimally for effective service delivery. 7. Participation in ILT and PT	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x

S/N	OBJECTIVES	INITIATIVE	KPIs	PERFORMANCE TARGET	JOURNEY TRACKER	RESPONSIBLE	TIMELINE		2024				2025				2026				2027			
							OUTPUT	ACTIVITY	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
		Malaria (ATM) commodities, and Narcotic drugs as a pilot)	Proportion of manufacturers complying with traceability requirements	80% of manufacturers complying with traceability requirements by 2027	Achieve 20% by 2024, 40% by 2025, 60% by 2026 and 80% by 2027	D, PMS D, NCS DGO	GS1 barcode printed on all ATM and Narcotic drugs	1. Ensure GS1 barcode printed on packaging of ATM and Narcotic drugs	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
4.2	Strengthen the Pharmacovigilance System for effective Adverse Event reporting and assessment	Expand and scale up the download and use of the Mobile Safety Application (Med Safety App) for ADR/AEFI reporting in Nigeria	Proportion of ICSRs received through electronic platforms	80% ADR reports submitted through electronic platforms yearly	Achieve 80% yearly	D, PV	ADR reported through electronic platforms	1. Conduct Active Surveillance for high-risk/ new pharmaceuticals. 2. Identify facilities to be used as sentinel sites for active surveillance. 3. Develop protocol for active surveillance. 4. Ethical review, clearance, or approval of protocol and conformity to international best standards 5. Identify and deploy tools for PV data collection and reporting in strict adherence to relevant PV guidelines and SOPs. 6. Sustained awareness creation on use of Med Safety App and e-reporting for reporting of Adverse events following immunizations and Adverse Drug Reactions.	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
			Percentage of Causality assessment conducted for received ICSRs	90% of received ICSRs assessed	Achieve 60% by 2024, 70% by 2025, 80% by 2026 and 90% by 2027	D PV	Causality assessment carried out	1. Carry out causality assessment of ICSRs	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
			Percentage of ADR/AEFI uploaded to Vigibase and VigiFlow	100% of ADR/AEFI uploaded to Vigibase and VigiFlow	Achieve 60% by 2024, 70% by 2025, 80% by 2026 and 100% by 2027	D PV	ADR/AEFI uploaded to VigiFlow and Vigibase	1. Upload ADR/AEFI to VigiFlow and Vigibase	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x
			Improve PV inspections of Pharmaceutical Manufacturers and Marketing Authorization	Proportion of scheduled PV inspections of Pharmaceutical Manufacturers and Marketing	Eight PV inspections conducted by 2027	Conduct 2 PV inspections c annually.	D, PV	Scheduled PV inspections conducted.	(i) Conduct PV inspection in compliance with National PV Policy and NAFDAC Good PV Practice Guidelines (ii) Effective RMP monitoring of MAHs	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x

S/N	OBJECTIVES	INITIATIVE	KPIs	PERFORMANCE TARGET	JOURNEY TRACKER	RESPONSIBLE	TIMELINE		2024				2025				2026				2027			
							OUTPUT	ACTIVITY	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
		Holders across the 36 states including FCT	Authorization Holders across the 36 states including FCT conducted.																					
Pillar 5	Efficient Financial and Performance Management																							
	Goal: To Promote, Sustain, and reinforce transparency and accountability in the management of the financial resources of the Agency.																							
5.1	Sustain a Responsible and Balanced Budgeting System	Enhance processes for tracking Resource Utilization.	Proportion of the approved budget implemented within specified timeline.	90% of planned/approved budget implemented yearly.	Achieve 90% yearly	D, F&A	Improved evaluation of financial goals.	1.Examination of the Agency’s financial records. 2.Reports on levels of compliance with laid down rules, regulations and procedures for keeping and recording govt. accounting books as stipulated by financial regulation, constitution, GAAP and other extant circulars.																
		Sustain the Standardized Financial Reporting Format.	Compliance level with IPSAS	Track 100% compliance with IPSAS	Sustain 100% compliance till 2027	D, F&A	Resource utilization tracked	Deploy ICT mechanism for tracking resource utilization																
		Sustain existing Internal Control Systems.	Proportion of revenue reconciled	100% of revenue GL reconciled		D, F&A	Resource utilization tracked	Deploy ICT mechanism for tracking resource utilization																
5.2	Strengthen the Performance Management System of the Agency	Strengthen the survey system for Data Integrity and evidence-based decision.	Proportion of approved surveys implemented	Implement 100% of approved surveys	Achieve 100% yearly.	D, PRS	Developed survey tools deployed.	1. Develop survey tools 2. deployment of survey tools 3. data analysis and management 4. report writing 5. disseminate survey findings 6. reports archiving																
		Strengthen the Monitoring and Evaluation System.	Proportion of scheduled M&E exercise conducted.	Sixteen (16) M&E Exercises conducted by 2027.	Conduct 4 M&E exercises yearly	D, PRS	M&E exercise conducted for evidence-based decision making	1. Develop/Review M&E tools 2. Schedule M&E exercise 3. Conduct M&E Exercise 4. Evaluate findings 5. Report writing 6. Disseminate findings																
			Proportion of reports monitored for timeliness	100% of reports monitored for timeliness	70% by 2024, 80% by 2025, 90% by 2026, 100% by 2027	D PRs	Periodic reports collated	1. Receive and collate periodic reports from Directorates/units/zones																

S/N	OBJECTIVES	INITIATIVE	KPIs	PERFORMANCE TARGET	JOURNEY TRACKER	RESPONSIBLE	TIMELINE		2024				2025				2026				2027							
							OUTPUT	ACTIVITY	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4				
								Software to help bring more spend under management.																				
		Reduce Procurement Cycle	Proportion of Procurements completed within timelines	90% of Procurement Activities done within timelines yearly	Achieve 90%, yearly	DG Head, Procurement	Procurements completed within timelines	1. Minimize the time it takes to produce and approve a requisition 2. Get approved Purchase Orders (PO) into the hands of vendors more quickly 3. Proactively monitor open orders 4. Provide vendor self-service portals to empower vendors to enter their own invoices	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x	x